1607-17-6

Usage

Uses

Vasodilator (coronary).

Brand name

Petrin (Parke-Davis).

Safety Profile

Poison by intraperitoneal route. When heated to decomposition it emits acrid smoke and irritating vapors.

InChI:InChI=1/C5H9N3O10/c9-1-5(2-16-6(10)11,3-17-7(12)13)4-18-8(14)15/h9H,1-4H2

Upstream product

• 78-11-5 Pentaerythritol tetranitrate 
• 92303-24-7 pentaerythrityl trinitrate acetate 
• 99-05-8 meta-aminobenzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 121-47-1 3-aminobenzenesulfonic acid 
• 121-57-3 4-aminobenzene sulfonic acid 
• 115-77-5 Pentaerythritol 
• 260268-26-6 2,2-dimethyl-1-nitrooxy-2,2-bis(nitrooxymethyl)-4-oxa-5,5-diphenyl-5-silaheptane 
• 1522-92-5 2,2-bis(bromomethyl)-3-bromo-propan-1-ol 

Downstream Products

• 1607-00-7 pentaerythrityl mononitrate 
• 1607-01-8 2,2-bis(hydroxymethyl)propane-1,3-diol dinitrate 
• 1538580-28-7 (Z)-3-(nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 
• 1538580-33-4 (Z)-3-(nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-ylacetate 
• 1538580-38-9 (Z)-3-(nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment

A series of analogues of the non-steroidal anti-inflammatory drug (NSAID) sulindac 1 were synthesised tethered to nitric oxide (NO) donating functional groups. Sulindac shows antiproliterative effects against immortal PC3 cell lines. It was previously demonstrated that the effect can be enhanced when tethered to NO releasing groups such as nitrate esters, furoxans and sydnonimines. To explore this approach further, a total of fifty-six sulindac-NO analogues were prepared and they were evaluated as NO-releasing cytotoxic agents against prostate cancer (PCa) cell lines. Compounds 1k and 1n exhibited significant cytotoxic with IC50 values of 6.1 ± 4.1 and 12.1 ± 3.2 μM, respectively, coupled with observed nitric oxide release.

NO donors. Part 18: Bioactive metabolites of GTN and PETN-Synthesis and vasorelaxant properties

The vasodilators glyceryl trinitrate (GTN) and pentaerythrityl tetranitrate (PETN) are supposed to be degraded in vivo to the lower nitrates PETriN, PEDN, PEMN, 1,2-GDN, 1,3-GDN, 1-GMN, and 2-GMN. We synthesized these bioactive metabolites as reference compounds for pharmacokinetic studies. The use of HPLC-methods for monitoring the stepwise reduction of PETN to lower nitrates and the syntheses of the glyceryl dinitrates proved advantageous. Furthermore, we measured the vasorelaxant properties of all metabolites by performing organ bath experiments with porcine pulmonary arteries. In general, the vasodilator potency increases with the number of nitrate moieties in the compound.

Nitrostated and nitrosylated prostaglandins, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

Pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same

The invention relates to novel compounds derived from pentaerythrite compounds of formula (XII) and (XVI), which can be used as pharmaceutically active substances, specially in the treatment of cardiac and circulatory diseases.

Pentaerythritol derivatives, their production and use and intermediates for their synthesis

The invention describes novel compounds derived from pentaerythritol of general formula I, XIV, XVI, XIX and XXII, the substituents being as defined in the description, which can be used as pharmaceutical active substances, especially for the treatment of cardiovascular diseases.

Synthesis of haptens and their protein conjugates for immunological determination of nitrate esters and nitramines

Isosteric, isopolar analogues of the nitrate ester pentaerythritol tetranitrate (PETN) and of the cyclic nitramine sym-cyclotrimethylene trinitramine (RDX) having a spacer arm have been linked to carrier proteins to provide immunologically active peptide conjugates. X-Ray structures of RDX, RDX analogue 10, and hapten 14 are compared to establish their conformational relationships. The Royal Society of Chemistry 2000.

N-NITRATION OF PRIMARY AROMATIC AMINES BY POLYNITRO AND POLYNITROXY COMPOUNDS

The possibility of N-nitration of primary aromatic amines containing SO3H and COOH groups by polynitro compounds C(NO2)4, (O2N)3CC(NO2)3, CH3C(NO2)3, C(NO2)3CH2CH2CN, and C(NO2)3CH2CH2COOCH3 and by polynitroxy compounds C(CH2ONO2)4 and HOCH2C(CH2ONO2)3 was investigated.In the presence of alkaline agents tetranitromethane, hexanitroethane, and pentaerythritol tetranitrate nitrate para- and meta-substituted aromatic amines with the formation of the corresponding nitroamine salts.Ortho-substituted amines do not enter into this reaction.